If the company can embrace influence rather than control, it has the opportunity to help define the open document standard, which will encourage even more growth in the category.

Given this recent softness—with the stock down about 10% over a month—the key question for investors is whether ORCL is a buy or a sell.

Oracle has added new capabilities to its electronic data capture platform, Clinical One Data Collection, to improve clinical trial efficiency and accelerate therapy development.  The enhancements ...